blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3415516

EP3415516 - HAPTENS OF RISPERIDONE AND PALIPERIDONE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.10.2022
Database last updated on 03.06.2024
FormerThe patent has been granted
Status updated on  12.11.2021
FormerGrant of patent is intended
Status updated on  28.06.2021
FormerExamination is in progress
Status updated on  20.11.2019
FormerRequest for examination was made
Status updated on  28.06.2019
FormerThe application has been published
Status updated on  16.11.2018
Most recent event   Tooltip31.05.2024Lapse of the patent in a contracting state
New state(s): MK		published on 03.07.2024 [2024/27]
Applicant(s)For all designated states
Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse / BE
[2018/51]
Inventor(s)01 / HASPESLAGH, Pieter Rik
Dorpsstraat 3
3545 Halen / BE
02 / VLIEGEN, Maarten
Hoge Heideweg 34
2310 Rijkevorsel / BE
03 / HRYHORENKO, Eric
45 Fraser Drive
Hilton, NY 14468 / US
04 / DECORY, Thomas R.
24 Round Trail Drive
Pittsford, NY 14534 / US
05 / SANKARAN, Banumathi
2 Bryant Road
Lexington, MA 02420 / US
 [2018/51]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2021/50]
Former [2018/51]McGuire, Gillian Margaret
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date18171270.420.08.2013
[2018/51]
Priority number, dateUS201261691469P21.08.2012         Original published format: US 201261691469 P
[2018/51]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3415516
Date:19.12.2018
Language:EN
[2018/51]
Type: B1 Patent specification 
No.:EP3415516
Date:15.12.2021
Language:EN
[2021/50]
Search report(s)(Supplementary) European search report - dispatched on:EP18.10.2018
ClassificationIPC:C07D487/04, C07D471/04, A61K31/519, C07K16/44
[2018/51]
CPC:
C07D471/04 (EP,CN,US); C07K16/44 (US); C07D487/04 (US);
C07K14/47 (CN); C07K14/77 (CN); C07K14/795 (CN)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/31]
Former [2018/51]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:HAPTENE AUS RISPERIDON UND PALIPERIDON[2018/51]
English:HAPTENS OF RISPERIDONE AND PALIPERIDONE[2018/51]
French:HAPTÈNES DE RISPÉRIDONE ET DE PALIPÉRIDONE[2018/51]
Examination procedure19.06.2019Amendment by applicant (claims and/or description)
19.06.2019Examination requested  [2019/31]
19.06.2019Date on which the examining division has become responsible
25.11.2019Despatch of a communication from the examining division (Time limit: M04)
01.04.2020Reply to a communication from the examining division
14.07.2020Despatch of a communication from the examining division (Time limit: M04)
23.11.2020Reply to a communication from the examining division
29.06.2021Communication of intention to grant the patent
09.11.2021Fee for grant paid
09.11.2021Fee for publishing/printing paid
09.11.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP13753972.2  / EP2888263
Opposition(s)16.09.2022No opposition filed within time limit [2022/47]
Fees paidRenewal fee
08.05.2018Renewal fee patent year 03
08.05.2018Renewal fee patent year 04
08.05.2018Renewal fee patent year 05
31.05.2018Renewal fee patent year 06
15.08.2019Renewal fee patent year 07
13.08.2020Renewal fee patent year 08
13.08.2021Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU20.08.2013
AL15.12.2021
CY15.12.2021
CZ15.12.2021
DK15.12.2021
EE15.12.2021
FI15.12.2021
HR15.12.2021
LT15.12.2021
LV15.12.2021
MC15.12.2021
MK15.12.2021
RS15.12.2021
SE15.12.2021
SI15.12.2021
SK15.12.2021
SM15.12.2021
BG15.03.2022
NO15.03.2022
GR16.03.2022
IS15.04.2022
IE20.08.2022
LU20.08.2022
[2024/27]
Former [2024/21]HU20.08.2013
AL15.12.2021
CY15.12.2021
CZ15.12.2021
DK15.12.2021
EE15.12.2021
FI15.12.2021
HR15.12.2021
LT15.12.2021
LV15.12.2021
MC15.12.2021
RS15.12.2021
SE15.12.2021
SI15.12.2021
SK15.12.2021
SM15.12.2021
BG15.03.2022
NO15.03.2022
GR16.03.2022
IS15.04.2022
IE20.08.2022
LU20.08.2022
Former [2024/18]HU20.08.2013
AL15.12.2021
CZ15.12.2021
DK15.12.2021
EE15.12.2021
FI15.12.2021
HR15.12.2021
LT15.12.2021
LV15.12.2021
MC15.12.2021
RS15.12.2021
SE15.12.2021
SI15.12.2021
SK15.12.2021
SM15.12.2021
BG15.03.2022
NO15.03.2022
GR16.03.2022
IS15.04.2022
IE20.08.2022
LU20.08.2022
Former [2023/33]AL15.12.2021
CZ15.12.2021
DK15.12.2021
EE15.12.2021
FI15.12.2021
HR15.12.2021
LT15.12.2021
LV15.12.2021
MC15.12.2021
RS15.12.2021
SE15.12.2021
SI15.12.2021
SK15.12.2021
SM15.12.2021
BG15.03.2022
NO15.03.2022
GR16.03.2022
IS15.04.2022
IE20.08.2022
LU20.08.2022
Former [2023/21]AL15.12.2021
CZ15.12.2021
DK15.12.2021
EE15.12.2021
FI15.12.2021
HR15.12.2021
LT15.12.2021
LV15.12.2021
MC15.12.2021
RS15.12.2021
SE15.12.2021
SI15.12.2021
SK15.12.2021
SM15.12.2021
BG15.03.2022
NO15.03.2022
GR16.03.2022
IS15.04.2022
LU20.08.2022
Former [2023/16]AL15.12.2021
CZ15.12.2021
DK15.12.2021
EE15.12.2021
FI15.12.2021
HR15.12.2021
LT15.12.2021
LV15.12.2021
MC15.12.2021
RS15.12.2021
SE15.12.2021
SI15.12.2021
SK15.12.2021
SM15.12.2021
BG15.03.2022
NO15.03.2022
GR16.03.2022
IS15.04.2022
Former [2023/01]AL15.12.2021
CZ15.12.2021
DK15.12.2021
EE15.12.2021
FI15.12.2021
HR15.12.2021
LT15.12.2021
LV15.12.2021
RS15.12.2021
SE15.12.2021
SI15.12.2021
SK15.12.2021
SM15.12.2021
BG15.03.2022
NO15.03.2022
GR16.03.2022
IS15.04.2022
Former [2022/49]AL15.12.2021
CZ15.12.2021
DK15.12.2021
EE15.12.2021
FI15.12.2021
HR15.12.2021
LT15.12.2021
LV15.12.2021
RS15.12.2021
SE15.12.2021
SK15.12.2021
SM15.12.2021
BG15.03.2022
NO15.03.2022
GR16.03.2022
IS15.04.2022
Former [2022/46]CZ15.12.2021
DK15.12.2021
EE15.12.2021
FI15.12.2021
HR15.12.2021
LT15.12.2021
LV15.12.2021
RS15.12.2021
SE15.12.2021
SK15.12.2021
SM15.12.2021
BG15.03.2022
NO15.03.2022
GR16.03.2022
IS15.04.2022
Former [2022/42]CZ15.12.2021
EE15.12.2021
FI15.12.2021
HR15.12.2021
LT15.12.2021
LV15.12.2021
RS15.12.2021
SE15.12.2021
SK15.12.2021
SM15.12.2021
BG15.03.2022
NO15.03.2022
GR16.03.2022
IS15.04.2022
Former [2022/35]CZ15.12.2021
EE15.12.2021
FI15.12.2021
HR15.12.2021
LT15.12.2021
LV15.12.2021
RS15.12.2021
SE15.12.2021
SK15.12.2021
SM15.12.2021
BG15.03.2022
NO15.03.2022
GR16.03.2022
Former [2022/33]FI15.12.2021
HR15.12.2021
LT15.12.2021
LV15.12.2021
RS15.12.2021
SE15.12.2021
SM15.12.2021
BG15.03.2022
NO15.03.2022
GR16.03.2022
Former [2022/25]FI15.12.2021
HR15.12.2021
LT15.12.2021
LV15.12.2021
RS15.12.2021
SE15.12.2021
BG15.03.2022
NO15.03.2022
GR16.03.2022
Former [2022/24]FI15.12.2021
HR15.12.2021
LT15.12.2021
LV15.12.2021
RS15.12.2021
SE15.12.2021
BG15.03.2022
GR16.03.2022
Former [2022/22]FI15.12.2021
LT15.12.2021
RS15.12.2021
BG15.03.2022
Former [2022/21]RS15.12.2021
BG15.03.2022
Former [2022/19]BG15.03.2022
Documents cited:Search[A]WO2011115733  (SALADAX BIOMEDICAL INC [US], et al) [A] 1-15* claims; examples; *
by applicantUS4166452
 US2006251592
 US2011245224
 US8088594
 WO2012012595
    - VAN OS, J.; KAPUR, S, "Schizophrenia", Lancet, (20090000), vol. 374, pages 635 - 645
    - ABDEL-BAKI, A.; OUELLET-PLAMONDON, C.; MALLA, A., "Pharmacotherapy Challenges in Patients with First-Episode Psychosis", Journal of Affective Disorders, (20120000), vol. 138, doi:doi:10.1016/j.jad.2012.02.029, pages S3 - S14, XP028473112

DOI:   http://dx.doi.org/10.1016/j.jad.2012.02.029
    - LIEBERMAN, J. A.; STROUP, T. S.; MCEVOY, J. P.; SWARTZ, M. S.; ROSENHECK, R. A.; PERKINS, D. 0.; KEEFE, R. S. E.; DAVIS, S. M.; DA, "Effectiveness of Antipyschotic Drugs in Patients with Chronic Schizophrenia", New England Journal of Medicine, (20050000), vol. 353, no. 12, doi:doi:10.1056/NEJMoa051688, pages 1209 - 1223, XP055179238

DOI:   http://dx.doi.org/10.1056/NEJMoa051688
    - WOESTENBORGHS et al., "On the selectivity of some recently developed RIA's", Methodological Surveys in Biochemistry and Analysis, (19900000), vol. 20, pages 241 - 246
    - HEYKANTS et al., "The Pharmacokinetics of Risperidone in Humans: A Summary", J Clin Psychiatry, (19940000), vol. 55/5, no. 13-17
    - HUANG et al., "Pharmacokinetics of the noveL anti-psychotic agent risperidone and the prolactin response in healthy subjects", Clin Pharmacol Ther, (19930000), vol. 54, pages 257 - 268
    - Pharm Res., (19920000), vol. 9, no. 11, pages 1375 - 9
    - Annali Dell'Istituto Superiore di Sanita, (19910000), vol. 27, no. 1, pages 167 - 74
    - Annali Dell'lstituto Superiore di Sanita, (19910000), vol. 27, no. 1, pages 149 - 54
    - Immunology Letters, (19910000), vol. 28, no. Ί, pages 79 - 83
    - BRINKLEY, M., A., Bioconjugate Chem., (19920000), vol. 3, pages 2 - 13
    - "Houben-Weyl", BENOITON, N.L., Methods of Organic Chemistry, Thieme Stuttgart, vol. E22
    - WU, Organic Letters, (20040000), vol. 6, no. 24, page 4407
    - CHEMICAL ABSTRACTS, Database accession no. 74124-79-1
    - WILBUR, Bioconjugate Chem., (20040000), vol. 75, no. 1, page 203
    - CHEMICAL ABSTRACTS, Database accession no. 125700-67-6
    - PRUHS, S., Org. Process, Res. Dev., (20060000), vol. 10, page 441
    - CHEMICAL ABSTRACTS, Database accession no. 2592-95-2
    - KÖNIG W.; GEIGER, R., Chem. Ber., (19700000), vol. 103, no. 3, page 788
    - CHEMICAL ABSTRACTS, Database accession no. 165534-43-0
    - LIU, H., Chinese Chemical Letters, (20020000), vol. 13, no. 7, page 601
    - CHEMICAL ABSTRACTS, Database accession no. 68641-49-6
    - DIAGO-MESEGUER, J, Synthesis, (19800000), vol. 7, pages 547 - 51
    - LI, Z., Phosphorus, Sulfur and Silicon and the Related Elements, (20030000), vol. 178, no. 2, pages 293 - 297
    - ANNUNZIATO, M.E.; PATEL, U.S.; RANADE, M.; PALUMBO, P.S., Bioconjugate Chem., (19930000), vol. 4, pages 212 - 218
    - MALACHOWSKI, WILLIAM P.; COWARD, JAMES K., Journal of Organic Chemistry, (19940000), vol. 59, no. 25, page 7616
    - ALIOUANE, L., Tetrahedron Letters, (20110000), vol. 52, no. 28, page 8681
    - CHAMOW, S.M.; KOGAN, T.P.; PEERS, D.H.; HASTINGS, R.C.; BYRN, R.A.; ASKENASZI, A., J. Biol. Chern., (19920000), vol. 267, no. 22, page 15916
    - CHEMICAL ABSTRACTS, Database accession no. 55750-61-3
    - CHEMICAL ABSTRACTS, Database accession no. 151199-81-4
    - PARK, J.W., Bioconjugate Chem., (20120000), vol. 23, no. 3, page 350
    - GHETIE, V. et al., Bioconjugate Chem., (19900000), vol. 1, pages 24 - 31
    - CHEMICAL ABSTRACTS, Database accession no. 76931-93-6
    - BILAH, M., Bioelectrochemistry, (20100000), vol. 80, no. 1, page 49
    - KIRLEY, T.L., Analytical Biochemistry, (19890000), vol. 180, no. 2, page 231
    - CHEMICAL ABSTRACTS, Database accession no. 3483-12-3
    - CLELAND, W., Biochemistry, (19640000), vol. 3, pages 480 - 482
    - WANG, J., L., Bioorganic and Med. Chem. Letters, (20100000), vol. 20, page 7159
    - KOHLER; MILSTEIN, Nature, (19750000), vol. 256, pages 495 - 497
    - MADDOX et al., J. Exp. Med., (19830000), vol. 158, page 12111
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.